Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial

被引：0
|
作者：
Ashina, M. [1 ]
Tepper, S. J. [2 ]
Reuter, U. [3 ]
Blumenfeld, A. M. [4 ]
Hutchinson, S. [5 ]
Xia, J. [6 ]
Miceli, R. [6 ]
Severt, L. [6 ]
Finnegan, M. [6 ]
Trugman, J. M. [6 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Glostrup, Denmark
[2] Geisel Sch Med Dartmouth, Hanover, NH USA
[3] Charite, Berlin, Germany
[4] Headache Ctr Southern Calif, Carlsbad, CA USA
[5] Orange Cty Migraine & Headache Ctr, Irvine, CA USA
[6] AbbVie, Madison, NJ USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0301
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [1] Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 163 - 163
  • [2] Atogepant 60 mg once-daily shows efficacy for the preventive treatment of migraine: Results from a 52-week open-label extension trial
    Ashina, M.
    Tepper, S. J.
    Reuter, U.
    Blumenfeld, A. M.
    Hutchinson, S.
    Xia, J.
    Miceli, R.
    Severt, L.
    Finnegan, M.
    Trugman, J. M.
    HEADACHE, 2021, 61 : 91 - 92
  • [3] Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial
    Ashina, Messoud
    Tepper, Stewart J.
    Reuter, Uwe
    Blumenfeld, Andrew M.
    Hutchinson, Susan
    Xia, Jing
    Miceli, Rosa
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel M.
    HEADACHE, 2023, 63 (01): : 79 - 88
  • [4] Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial
    Lipton, Richard B.
    Halker Singh, Rashmi B.
    Mechtler, Laszlo
    Mcvige, Jennifer
    Ma, Julia
    Yu, Sung Yun
    Stokes, Jonathan
    Dabruzzo, Brett
    Gandhi, Pranav
    Ashina, Messoud
    CEPHALALGIA, 2023, 43 (09)
  • [5] Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
    Croop, Robert
    Ailani, Jessica
    Kudrow, David
    Smith, Timothy
    Lipton, Richard
    Thiry, Alexandra
    Jensen, Christopher
    Kamen, Lisa
    NEUROLOGY, 2023, 100 (17)
  • [6] Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study
    Hutchinson, Susan
    Mullin, Kathleen
    Pavlovic, Jelena
    Lipton, Richard
    Jensen, Christopher
    Thiry, Alexandra
    Kamen, Lisa
    Croop, Robert
    NEUROLOGY, 2023, 100 (17)
  • [7] Effects of rimegepant 75 mg on monthly migraine days: A 52-week, open-label extension study
    Ailani, J.
    Kudrow, D.
    Smith, T. R.
    Lipton, R. B.
    Thiry, A. C.
    Jensen, C. M.
    Kamen, L.
    Coric, V
    Croop, R.
    HEADACHE, 2022, 62 : 139 - 140
  • [8] Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study
    Ailani, Jessica
    Kudrow, David
    Smith, Timothy
    Lipton, Richard B.
    Goadsby, Peter J.
    Thiry, Alexandra
    Jensen, Christopher M.
    Kamen, Lisa
    Coric, Vladimir
    Croop, Robert
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 132 - 134
  • [9] Patterns of medication utilization and migraine frequency in adults using rimegepant for both preventive and acute treatment for migraine: Results from a 52-week, open-label extension study
    Hutchinson, S.
    Goodrich, R.
    HEADACHE, 2022, 62 (07): : 926 - 927
  • [10] Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial
    Klein, Brad C.
    Miceli, Rosa
    Severt, Lawrence
    McAllister, Peter
    Mechtler, Laszlo
    McVige, Jennifer
    Diamond, Merle
    Marmura, Michael J.
    Guo, Hua
    Finnegan, Michelle
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (01)
12345